149 related articles for article (PubMed ID: 20831980)
1. Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.
Takizawa I; Nishiyama T; Hara N; Hoshii T; Ishizaki F; Miyashiro Y; Takahashi K
Cancer Lett; 2010 Nov; 297(2):226-30. PubMed ID: 20831980
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
4. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment?
Geldof AA; Dijkstra I; Newling DW; Rao BR
Anticancer Res; 1995; 15(4):1349-54. PubMed ID: 7654020
[TBL] [Abstract][Full Text] [Related]
8. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
10. Sex steroid hormone metabolism and prostate cancer.
Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
[TBL] [Abstract][Full Text] [Related]
11. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
14. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Evaul K; Li R; Papari-Zareei M; Auchus RJ; Sharifi N
Endocrinology; 2010 Aug; 151(8):3514-20. PubMed ID: 20534728
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17. The 3beta-hydroxysteroid dehydrogenase inhibitor trilostane shows antidepressant properties in mice.
Espallergues J; Givalois L; Temsamani J; Laruelle C; Maurice T
Psychoneuroendocrinology; 2009 Jun; 34(5):644-59. PubMed ID: 19117688
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
19. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
20. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells.
Sun YH; Gao X; Tang YJ; Xu CL; Wang LH
J Androl; 2006; 27(5):671-8. PubMed ID: 16728719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
